Hypercholesterolemia and hypertriglyceridemia represented the most common treatment-related AEs, and the antitumor activity of lorlatinib was seen across a range of ALK resistance mutations, including G1202R. The gene discussed is ALK; the disease is familial hypercholesterolemia.